Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2017’, provides in depth analysis on Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology, Metabolic Disorders and Other Diseases under development targeting Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Advinus Therapeutics Ltd

Allergan Plc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Brickell Biotech Inc

Bristol-Myers Squibb Company

Celgene Corp

Eli Lilly and Company

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Lead Pharma Holding BV

Lycera Corp

Maruho Co Ltd

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development

AbbVie Inc

Advinus Therapeutics Ltd

Allergan Plc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Brickell Biotech Inc

Bristol-Myers Squibb Company

Celgene Corp

Eli Lilly and Company

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Lead Pharma Holding BV

Lycera Corp

Maruho Co Ltd

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles

ABBV-553 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-6039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0284 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-6000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRC-39815 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2981278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMU-366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-71 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3534 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-55716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-56056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis and Psoriatic Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RORC for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-2211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGFTX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMP-778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPR-66 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-43742 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-45489 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones

Featured News & Press Releases

Jul 10, 2017: Phenex announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I

Jan 04, 2017: Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors

Nov 04, 2016: Lycera Announces Publication of Immuno-Oncology Research, Demonstrating Differentiated Mechanism of RORgamma Agonists

Sep 26, 2016: GENFIT: Successful identification of RORt inverse agonists as candidates for regulatory pre-IND studies

Aug 01, 2016: Arrien Pharmaceuticals Provides Update on ARN-6039

Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer

Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis

May 16, 2016: Arrien Pharmaceuticals Initiates Phase I Clinical trials of ARN-6039

May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug

Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039

Apr 19, 2016: Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research Annual Meeting

Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis

Dec 17, 2015: Phenex reaches milestone in collaboration with Janssen

Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742

Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1)

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AbbVie Inc, H2 2017

Pipeline by Advinus Therapeutics Ltd, H2 2017

Pipeline by Allergan Plc, H2 2017

Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017

Pipeline by Biogen Inc, H2 2017

Pipeline by Brickell Biotech Inc, H2 2017

Pipeline by Bristol-Myers Squibb Company, H2 2017

Pipeline by Celgene Corp, H2 2017

Pipeline by Eli Lilly and Company, H2 2017

Pipeline by Genentech Inc, H2 2017

Pipeline by Genfit SA, H2 2017

Pipeline by GlaxoSmithKline Plc, H2 2017

Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Pipeline by Lead Pharma Holding BV, H2 2017

Pipeline by Lycera Corp, H2 2017

Pipeline by Maruho Co Ltd, H2 2017

Pipeline by Nuevolution AB, H2 2017

Pipeline by Orphagen Pharmaceuticals Inc, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Phenex Pharmaceuticals AG, H2 2017

Pipeline by Reata Pharmaceuticals Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports